Maze Therapeutics, Inc. (MAZE) Earnings Call Transcripts

Maze Therapeutics, Inc.'s Latest Earnings Call - June 10, 2026

Maze Therapeutics reported its earnings for Q2 FY2026, focusing on its lead assets 829 for kidney disease and 782 for PKU. The company highlighted promising data from its HORIZON Phase II study for 829, demonstrating a 62% reduction in UACR in FSGS patients, which is significant given the lack of effective treatments. Maze plans to initiate a pivotal study for 829 in the first half of 2027. For 782, Maze showed a 40x increase in urinary phenylalanine excretion, indicating potential best-in-class efficacy for PKU. The company maintains a strong cash position of $528 million, providing runway into 2029. No changes in revenue or earnings guidance were mentioned.

Reported metrics

Guidance from management

Maze plans to start a pivotal study for 829 in the first half of 2027 and expects full readout from the HORIZON study by the end of 2026. The cash runway is guided through 2029.

What management said

Okay. So we have -- we'll have the full readout for Horizon, the end of '26 and '27. So we will have the 3 cohorts of FSGS nondiabetic patients as well as diabetic patients, 10 to 15 patients per cohort that will allow us to really understand and tease out the signal -- in parallel, what we're doing is advancing the non-diabetic patient cohort for pivotal planning, which we expect to start in the first half of 2027.

So yes, we just reported with a recent raise, we had a little over $528 million. That funds multiple catalysts that have been described today. So -- not only does it complete the Horizon study, which we'll have the data later this year, early next, the PKU proof-of-concept study, the CKD proof-of-concept study and allows us to even initiate the pivotal study for 829 in kidney disease.

What analysts pressed on

Analysts expressed interest in the differentiation of 829 in the competitive landscape and the potential regulatory pathways for non-FSGS patients. Concerns about the ability to achieve clinically meaningful reductions in proteinuria across diverse patient populations were noted.

Main topics on the call

• HORIZON Study Results — Maze's HORIZON Phase II study for 829 showed a 62% reduction in UACR in FSGS patients, exceeding previous benchmarks and demonstrating a competitive profile. Management plans to start a pivotal study in 2027.
• PKU Treatment Potential — Maze 782 demonstrated a 40x increase in urinary phenylalanine excretion in Phase I, suggesting potential best-in-class efficacy for PKU treatment. This could address the unmet need for patients on restrictive diets.
• APOL1 Kidney Disease Differentiation — Maze's 829 is differentiated by its dual mechanism, blocking and disrupting pore assembly, which could offer superior efficacy compared to competitors in APOL1 kidney disease.
• Regulatory Pathway Clarity — The regulatory path for 829 in FSGS is clear, with proteinuria reduction as an approvable endpoint. Ongoing studies may further clarify pathways for non-FSGS patients.

Read the full Maze Therapeutics, Inc. transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 5 Maze Therapeutics, Inc. earnings call transcripts on record, spanning September 11, 2025 to June 10, 2026. Based on this history, Maze Therapeutics, Inc. reports quarterly. The most recent call on file is dated June 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

MAZE

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

5

First call

September 11, 2025

Most recent

June 10, 2026

Reporting cadence

quarterly